ARTICLE | Clinical News
INGN 201 (Ad5CMV-p53): Completed Phase III trial review
March 13, 2000 8:00 AM UTC
Introgen Therapeutics Inc., Austin, Texas Product: INGN 201 (Ad5CMV-p53) Business: Cancer Therapeutic category: Gene therapy, Cell proliferation Target: Tumor cells Description: Adenoviral p53 tumor s...